| RRC ID |
69143
|
| 著者 |
Kono M, Komatsuda H, Yamaki H, Kumai T, Hayashi R, Wakisaka R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Katada A, Hayashi T, Kobayashi H, Harabuchi Y.
|
| タイトル |
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma.
|
| ジャーナル |
Oncoimmunology
|
| Abstract |
Fibroblast growth factor receptor 1 (FGFR1) is overexpressed in multiple types of solid tumors, including head and neck squamous cell carcinoma (HNSCC). Being associated with poor prognosis, FGFR1 is a potential therapeutic target for aggressive tumors. T cell-based cancer immunotherapy has played a central role in novel cancer treatments. However, the potential of antitumor immunotherapy targeting FGFR1 has not been investigated. Here, we showed that FGFR-tyrosine kinase inhibitors (TKIs) augmented antitumor effects of immune checkpoint inhibitors in an HNSCC mouse model and upregulated tumoral MHC class I and MHC class II expression in vivo and in vitro. This upregulation was associated with the mitogen-activated protein kinase signaling pathway, which is a crucial pathway for cancer development through FGFR signaling. Moreover, we identified an FGFR1-derived peptide epitope (FGFR1305-319) that could elicit antigen-reactive and multiple HLA-restricted CD4+ T cell responses. These T cells showed direct cytotoxicity against tumor cells that expressed FGFR1. Notably, FGFR-TKIs augmented antitumor effects of FGFR1-reactive T cells against human HNSCC cells. These results indicate that the combination of FGFR-TKIs with immunotherapy, such as an FGFR1-targeting peptide vaccine or immune checkpoint inhibitor, could be a novel and robust immunologic approach for treating patients with FGFR1-expressing cancer cells.
|
| 巻・号 |
11(1)
|
| ページ |
2021619
|
| 公開日 |
2022-1-1
|
| DOI |
10.1080/2162402X.2021.2021619
|
| PII |
2021619
|
| PMID |
35003900
|
| PMC |
PMC8741288
|
| MeSH |
Animals
Carcinoma, Squamous Cell* / drug therapy
Carcinoma, Squamous Cell* / genetics
Cell Line, Tumor
Head and Neck Neoplasms* / drug therapy
Head and Neck Neoplasms* / genetics
Humans
Immunotherapy
Mice
Receptor, Fibroblast Growth Factor, Type 1 / genetics
Squamous Cell Carcinoma of Head and Neck / drug therapy
Squamous Cell Carcinoma of Head and Neck / genetics
T-Lymphocytes
|
| IF |
5.869
|
| リソース情報 |
| ヒト・動物細胞 |
HSC-2(RCB1945)
HSC-3(RCB1975)
HSC-4(RCB1902)
Sa3(RCB0980) |
